Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.

You may also be interested in...



‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly

Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.

‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly

Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.

Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial

Additional study for the antibiotic will take 18 months to complete, company says

Related Content

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel